Form 4: Hookipa Pharma Inc. Executive Acquires Stock Options
SEC Form 4 Filing
Mark Winderlich, Chief Development Officer of Hookipa Pharma Inc., acquired stock options on April 15, 2024.
Summary
- Mark Winderlich, Chief Development Officer of Hookipa Pharma Inc., reported changes in beneficial ownership to the SEC.
- On April 15, 2024, Winderlich acquired stock options to purchase 250,000 shares of common stock at an exercise price of $0.76, expiring on April 15, 2034.
- Additionally, Winderlich acquired stock options to purchase 50,000 shares of common stock at an exercise price of $0.76, expiring on April 15, 2034.
- The options vest over time, with 25% vesting on April 15, 2025, and the remainder vesting in 12 equal quarterly installments thereafter.
Sentiment
Score: 5
Explanation: Neutral sentiment as it's a standard regulatory filing related to executive compensation. The acquisition of stock options can be seen as a positive sign, but it's not a major event.
Positives
- The acquisition of stock options by a key executive could signal confidence in the company's future prospects.
Industry Context
Form 4 filings are routine disclosures required by the SEC to provide transparency into the transactions of company insiders. These filings are closely watched by investors to gauge management's sentiment and potential future performance.
Stakeholder Impact
- The acquisition of stock options by a key executive could positively influence shareholder sentiment.
Key Dates
| Date | Description |
|---|---|
| 04/15/2024 | Date of earliest transaction: Acquisition of stock options. |
| 04/15/2025 | 25% of the options vest. |
| 04/15/2034 | Expiration date of the stock options. |
| 04/17/2024 | Date of signature. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.